KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

The effect of once-weekly insulin icodec vs once-daily basal insulin on physical activity-attributed hypoglycaemia in type 2 diabetes: a post hoc analysis of ONWARDS 1-5.

Michael C Riddell, Simon Heller, Lisbeth Carstensen, Thaís M Pagliaro Rocha, Sara Kehlet Watt, Vincent C Woo

Diabetologia 68(7) 1416-1422

PMID40186685
PMCIDPMC12176998
DOI10.1007/s00125-025-06414-6
发表日期2025-04-05
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other;Fig. 2:AI 判定为 other。
摘要

摘要

AIMS/HYPOTHESIS: Physical activity increases the risk of hypoglycaemia in individuals with type 2 diabetes when basal or basal-bolus insulin therapy is administered. Once-weekly basal insulins may elevate the risk of physical activity-attributed hypoglycaemia compared with other basal insulins because the administered levels cannot be reduced in anticipation of increased physical activity. This post hoc analysis of five separate randomised trials (ONWARDS 1-5) aimed to examine physical activity-attributed hypoglycaemic episodes in adults with type 2 diabetes receiving either once-weekly basal insulin icodec (herein referred to as 'icodec') or once-daily basal insulins. METHODS: The ONWARDS 1-5 Phase 3a randomised controlled trials compared the efficacy and safety of once-weekly basal icodec vs once-daily basal insulin in insulin-naive (ONWARDS 1, 3 and 5) and insulin-experienced (ONWARDS 2 and 4) adults with type 2 diabetes. Participants self-monitored their blood glucose levels using a blood glucose meter and a digital diary. In each trial, suspected hypoglycaemia symptoms triggered additional self-measured blood glucose readings, and values indicative of hypoglycaemia were recorded in the participants' digital diary. Participants who experienced hypoglycaemic episodes were instructed to note any relation of each episode to physical activity. Hypoglycaemic episodes were classified as alert value (level 1: blood glucose <3.9 but ≥3.0 mmol/l), clinically significant (level 2: blood glucose <3.0 mmol/l) or severe (level 3: cognitive impairment requiring external assistance). The proportions of hypoglycaemic episodes that were attributed to physical activity and the ORs of having a physical activity-attributed hypoglycaemic episode were calculated for the two basal insulin types (once-weekly vs once-daily) for each of the five trials. RESULTS: Across all trials, there were no consistent differences between icodec and the once-daily insulin comparators in the proportions of hypoglycaemic episodes that were attributed to physical activity; these episodes were mainly alert value or clinically significant hypoglycaemic episodes. In both insulin-naive and insulin-experienced participants, the incidence of physical activity-attributed clinically significant or severe hypoglycaemic episodes was consistently ≤3.0% in ONWARDS 1, 2, 3 and 5. In ONWARDS 4, the incidence of physical activity-attributed hypoglycaemic episodes was numerically higher in both treatment groups (18.6% [icodec] vs 17.9% [insulin glargine U100]), which was expected given the basal-bolus insulin regimen. Across all trials, there were no statistically significant differences in the odds of experiencing a physical activity-attributed clinically significant or severe hypoglycaemic episode with icodec vs once-daily insulin comparators. The frequency of recurrent clinically significant or severe hypoglycaemic episodes in the 24 h after a physical activity-attributed clinically significant or severe hypoglycaemic episode was low, with no such episodes in ONWARDS 1, 3 and 5. In contrast, in ONWARDS 2 and 4, the frequency of recurrent clinically significant hypoglycaemic episodes in the 24 h after a physical activity-attributed clinically significant or severe hypoglycaemic episode was numerically higher with icodec vs the once-daily insulin comparators, whilst no additional severe episodes were reported in any participants across the trials. CONCLUSIONS/INTERPRETATION: These findings do not suggest that there is an additional increase in hypoglycaemia risk attributed to physical activity with once-weekly basal icodec vs once-daily basal insulins in adults with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT04460885 (ONWARDS 1), NCT04770532 (ONWARDS 2), NCT04795531 (ONWARDS 3), NCT04880850 (ONWARDS 4) and NCT04760626 (ONWARDS 5).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 Proportion of hypoglycaemic episodes that were attributed to physical activity during the on-treatment period of ONWARDS 1–5. The on-treatment period was defined as the onset date on or after the first dose of the trial product and no later than the first date of either the follow-up visit, the last date on trial product +5 weeks for once-daily insulin and +6 weeks for once-weekly insulin, or the end date for the in-trial period (defined as the time from randomisation to whichever occurred first of the last direct participant–site contact, withdrawal of informed consent, the last participant–investigator contact before loss to follow-up, or death). Hypoglycaemia alert value was defined as a blood glucose value < 3.9 mmol/l but ≥3.0 mmol/l, confirmed by a blood glucose meter; clinically significant hypoglycaemia was defined as a blood glucose value < 3.0 mmol/l, confirmed by a blood glucose meter; severe hypoglycaemia was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. a The choice of the once-daily insulin analogue (insulin degludec, insulin glargine U100 or insulin glargine U300) was made at the discretion of the investigator. Aspart, insulin aspart; degludec, insulin degludec; glargine U100, insulin glargine U100; glargine U300, insulin glargine U300; icodec, insulin icodec; OD, once-daily
非 KM Figure
Fig. 2Fig. 2 Observed incidence of physical activity-attributed clinically significant or severe hypoglycaemia with icodec vs once-daily insulin comparators during the on-treatment period of ONWARDS 1–5. The table presents the number of participants in each treatment arm that were included in the analyses that are presented in the bar graph. The on-treatment period was defined as the onset date on or after the first dose of trial product and no later than the first date of either the follow-up visit, the last date on trial product +5 weeks for once-daily insulin and +6 weeks for once-weekly insulin, or the end date for the in-trial period (defined as the time from randomisation to whichever occurred first of the last direct participant–site contact, withdrawal of informed consent, the last participant–investigator contact before loss to follow-up, or death). The incidence of hypoglycaemia was analysed using a binary logistic regression model, with treatment, geographical region, sulfonylurea/glinide use (ONWARDS 3) and personal continuous glucose monitoring device use (ONWARDS 2 and 4) as fixed factors. Missing data were imputed using multiple imputations. Clinically significant hypoglycaemia was defined as a blood glucose value < 3.0 mmol/l, confirmed by a blood glucose meter; severe hypoglycaemia was defined as hypoglycaemia with severe cognitive impairment requiring external assistance for recovery. ORs (icodec/once-daily insulin comparator) are shown; there were no statistically significant differences between treatment arms in each trial (two-sided p values for the test of no treatment difference [with no correction for multiplicity] were p =0.1607, p =0.1103 and p =0.4640 for ONWARDS 1, ONWARDS 3 and ONWARDS 5, respectively, and p =0.8621 and p =0.7250 for ONWARDS 2 and ONWARDS 4, respectively). a The choice of the once-daily insulin analogue (degludec, glargine U100 or glargine U300) was made at the discretion of the investigator. Aspart, insulin aspart; degludec, insulin degludec; glargine U100, insulin glargine U100; glargine U300, insulin glargine U300; icodec, insulin icodec; OD, once-daily
非 KM Figure